浩博医药AusperBio is a startup based in China, most recent round Series B.
浩博医药AusperBio is a company headquartered in China. Its most recent tracked round is Series B.
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative antisense oligonucleotide (ASO) therapeutics, primarily targeting hepatitis B virus (HBV) and other diseases including viral infections, metabolic, genetic, and immune disorders.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.